AACR 2018: Selective inhibitor shows early promise in patients with RET-altered cancers
BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well…
Browsing: RET-altered cancers
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- AACR 2024: How cellular plasticity drives cancer metastasis
- AACR 2024: Proteogenomic signatures may help identify risk of prostate cancer progression in patients with African and European ancestries
- AACR 2024: Investigational personalised vaccine provides clinical benefit for some patients with resected head and neck cancers
- AACR 2024: Artificial intelligence analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer
- AACR 2024: AZD1390 with radiotherapy shows manageable safety profile and preliminary efficacy for patients with glioblastoma in phase I trial
- AACR 2024: An exosome-based liquid biopsy shows promise for early detection of pancreatic cancer
- Targeting vulnerability in B-cell development leads to novel drug combination for leukaemia
- The surprising connection between male infertility and family cancer risk